[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  $6163b Market volatility continues to dominate discussions as $6163b faces downward price pressure. Community members are actively engaging, seeking clarity amidst regulatory uncertainties. ### About $6163b $6163b is a digital asset focused on decentralized finance and blockchain technology. ### Insights [#](/topic/$6163b/insights) - $6163b engagements hit 5833 which is XXX% higher than it's daily average. - $6163b Creators hit a 52-Week high of X for the day - $6163b Creators hit an all time of X for the day - $6163b Mentions hit a 52-Week high of X for the day - $6163b Mentions hit an all time of X for the day - $6163b Engagements hit a 52-Week high of XXXXXX for the day - $6163b Engagements hit an all time of XXXXXX for the day ### Engagements: XXXXX [#](/topic/$6163b/interactions) ---  [Engagements 24-Hour Time-Series Raw Data](/topic/$6163b/time-series/interactions.tsv) **Current Value**: XXXXX **Daily Average**: XXXXX **6 Months**: XXXXXX +5,187% **1 Year**: XXXXXX +9,440% **1-Year High**: XXXXXX on 2025-10-30 **1-Year Low**: X on 2025-06-21 | Social Network | X | | -------------- | - | | Engagements | XXXXX | ### Mentions: X [#](/topic/$6163b/posts_active) ---  [Mentions 24-Hour Time-Series Raw Data](/topic/$6163b/time-series/posts_active.tsv) **Current Value**: X **Daily Average**: X **6 Months**: XX +25% **1 Year**: XX +1,600% **1-Year High**: X on 2025-11-01 **1-Year Low**: X on 2024-12-04 | Social Network | X | | -------------- | - | | Mentions | XX | ### Creators: X [#](/topic/$6163b/contributors_active) ---  [Creators 24-Hour Time-Series Raw Data](/topic/$6163b/time-series/contributors_active.tsv) X unique social accounts have posts mentioning $6163b in the last XX hours which is no change from in the previous XX hours **Daily Average**: X **6 Months**: XX +25% **1 Year**: XX +1,600% **1-Year High**: X on 2025-11-01 **1-Year Low**: X on 2024-12-04 **Top assets mentioned** In the posts about $6163b in the last XX hours [Eli Lilly and Company (LLY)](/topic/eli-lilly) [Eli Lilly and Company (LLY)](/topic/$lly) [Novo-Nordisk (NVO)](/topic/$nvo) **Top topics mentioned** In the posts about $6163b in the last XX hours [stocks healthcare](/topic/stocks-healthcare), [eli lilly](/topic/eli-lilly), [$lly](/topic/$lly), [$1760b](/topic/$1760b), [$1607b](/topic/$1607b), [$630b](/topic/$630b), [$635b](/topic/$635b), [eps](/topic/eps), [$652b](/topic/$652b), [$nvo](/topic/$nvo), [investment](/topic/investment), [money](/topic/money), [should be](/topic/should-be), [instead of](/topic/instead-of) ### Top Social Posts [#](/topic/$6163b/posts) --- Top posts by engagements in the last XX hours *Showing only X posts for non-authenticated requests. Use your API key in requests for full results.* "๐ฅ $LLY vs $NVO The Battle of the Obesity Kings $NVO is busy spending on acquisitions while $LLY just dropped another monster quarter ๐ช Eli Lilly Q3: ๐ฐ Revenue: $17.6B (vs $16.07B est) +54% YoY ๐ EPS (Non-GAAP): $XXXX (vs $XXXX est) ๐งพ Gross Margin: XXXX% ๐ FY25 Guidance Raised: Revenue: $63.063.5B (vs $61.63B est) EPS: $23.00$23.70 (vs $XXXXX est) CEO David Ricks: Lilly delivered another strong quarter driven by demand for our incretin portfolio. Were expanding globally scaling capacity and building the future of metabolic health. $LLY is executing flawlessly scaling innovating and" [X Link](https://x.com/rahuls61193/status/1983956540957557052) [@rahuls61193](/creator/x/rahuls61193) 2025-10-30T17:57Z XXX followers, XXX engagements "$LLY Eli Lilly Q325 Earnings Highlights ๐น Revenue: $17.60B (Est. $16.07B) ๐ข; UP +54% YoY ๐น EPS (Non-GAAP): $XXXX (Est. $5.89) ๐ข ๐น Gross Margin: XXXX% FY25 Guidance ๐น Revenue: $63.0B$63.5B (Est. $61.63B) ๐ข ๐น EPS (Non-GAAP): $23.00$23.70 (Est. $22.50) ๐ข ๐น Adj. Gross Margin: XX% ๐น Performance Margin: 45%46% (Non-GAAP) Segment ๐น Mounjaro: $6.52B; UP +109% YoY ๐น Zepbound: $3.59B; UP +185% YoY ๐น Verzenio: $1.47B; UP +7% YoY Other Metrics ๐น U.S. Revenue: $11.30B; UP +45% YoY ๐น OUS Revenue: $6.30B; UP +74% YoY CEO Commentary ๐ธ Lilly delivered another strong quarter with XX% revenue" [X Link](https://x.com/dominic_pirrone/status/1983905228639629703) [@dominic_pirrone](/creator/x/dominic_pirrone) 2025-10-30T14:34Z 5485 followers, XXX engagements "$LLY Eli Lilly reports Q3 EPS $XXXX consensus $XXXX -- Q3 revenue $17.6B consensus $16.07B. -- Raises FY25 EPS view to $23.00-$23.70 from $21.75-$23.00 consensus $XXXXX. -- Raises FY25 revenue view to $63B-$63.5B from $60B-$62B consensus $61.63B" [X Link](https://x.com/CorleoneDon77/status/1983855901418385467) [@CorleoneDon77](/creator/x/CorleoneDon77) 2025-10-30T11:17Z 6447 followers, XXX engagements "$NVO busy spending money on acquisitions. Value = unclear. Meanwhile $LLY with another great quarter. Maybe I should be investing in $LLY instead of $NVO Eli Lilly's Q3 numbers: - Revenue: $17.60B (Est. $16.07B) ๐ข+54% YoY - EPS (Non-GAAP): $XXXX (Est. $5.89) ๐ข - Gross Margin: 82.9%๐ข FY25 Guidance raised -- - Revenue: $63.0B$63.5B (Est. $61.63B) ๐ข - EPS (Non-GAAP): $23.00$23.70 (Est. $22.50) ๐ข $LLY CEO David Ricks: Lilly delivered another strong quarter with XX% revenue growth year-over-year driven by continued demand for our incretin portfolio". " We advanced Orforglipron through four" [X Link](https://x.com/TacticzH/status/1983854319381201002) [@TacticzH](/creator/x/TacticzH) 2025-10-30T11:11Z 29.5K followers, 28.8K engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
 $6163bMarket volatility continues to dominate discussions as $6163b faces downward price pressure. Community members are actively engaging, seeking clarity amidst regulatory uncertainties.
$6163b is a digital asset focused on decentralized finance and blockchain technology.
Engagements 24-Hour Time-Series Raw Data
Current Value: XXXXX
Daily Average: XXXXX
6 Months: XXXXXX +5,187%
1 Year: XXXXXX +9,440%
1-Year High: XXXXXX on 2025-10-30
1-Year Low: X on 2025-06-21  
| Social Network | X | 
|---|---|
| Engagements | XXXXX | 
Mentions 24-Hour Time-Series Raw Data
Current Value: X
Daily Average: X
6 Months: XX +25%
1 Year: XX +1,600%
1-Year High: X on 2025-11-01
1-Year Low: X on 2024-12-04  
| Social Network | X | 
|---|---|
| Mentions | XX | 
Creators 24-Hour Time-Series Raw Data
X unique social accounts have posts mentioning $6163b in the last XX hours which is no change from in the previous XX hours
Daily Average: X
6 Months: XX +25%
1 Year: XX +1,600%
1-Year High: X on 2025-11-01
1-Year Low: X on 2024-12-04  
Top assets mentioned In the posts about $6163b in the last XX hours
Eli Lilly and Company (LLY) Eli Lilly and Company (LLY) Novo-Nordisk (NVO)
Top topics mentioned In the posts about $6163b in the last XX hours
stocks healthcare, eli lilly, $lly, $1760b, $1607b, $630b, $635b, eps, $652b, $nvo, investment, money, should be, instead of
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"๐ฅ $LLY vs $NVO The Battle of the Obesity Kings $NVO is busy spending on acquisitions while $LLY just dropped another monster quarter ๐ช Eli Lilly Q3: ๐ฐ Revenue: $17.6B (vs $16.07B est) +54% YoY ๐ EPS (Non-GAAP): $XXXX (vs $XXXX est) ๐งพ Gross Margin: XXXX% ๐ FY25 Guidance Raised: Revenue: $63.063.5B (vs $61.63B est) EPS: $23.00$23.70 (vs $XXXXX est) CEO David Ricks: Lilly delivered another strong quarter driven by demand for our incretin portfolio. Were expanding globally scaling capacity and building the future of metabolic health. $LLY is executing flawlessly scaling innovating and"
X Link @rahuls61193 2025-10-30T17:57Z XXX followers, XXX engagements
"$LLY Eli Lilly Q325 Earnings Highlights ๐น Revenue: $17.60B (Est. $16.07B) ๐ข; UP +54% YoY ๐น EPS (Non-GAAP): $XXXX (Est. $5.89) ๐ข ๐น Gross Margin: XXXX% FY25 Guidance ๐น Revenue: $63.0B$63.5B (Est. $61.63B) ๐ข ๐น EPS (Non-GAAP): $23.00$23.70 (Est. $22.50) ๐ข ๐น Adj. Gross Margin: XX% ๐น Performance Margin: 45%46% (Non-GAAP) Segment ๐น Mounjaro: $6.52B; UP +109% YoY ๐น Zepbound: $3.59B; UP +185% YoY ๐น Verzenio: $1.47B; UP +7% YoY Other Metrics ๐น U.S. Revenue: $11.30B; UP +45% YoY ๐น OUS Revenue: $6.30B; UP +74% YoY CEO Commentary ๐ธ Lilly delivered another strong quarter with XX% revenue"
X Link @dominic_pirrone 2025-10-30T14:34Z 5485 followers, XXX engagements
"$LLY Eli Lilly reports Q3 EPS $XXXX consensus $XXXX -- Q3 revenue $17.6B consensus $16.07B. -- Raises FY25 EPS view to $23.00-$23.70 from $21.75-$23.00 consensus $XXXXX. -- Raises FY25 revenue view to $63B-$63.5B from $60B-$62B consensus $61.63B"
X Link @CorleoneDon77 2025-10-30T11:17Z 6447 followers, XXX engagements
"$NVO busy spending money on acquisitions. Value = unclear. Meanwhile $LLY with another great quarter. Maybe I should be investing in $LLY instead of $NVO Eli Lilly's Q3 numbers: - Revenue: $17.60B (Est. $16.07B) ๐ข+54% YoY - EPS (Non-GAAP): $XXXX (Est. $5.89) ๐ข - Gross Margin: 82.9%๐ข FY25 Guidance raised -- - Revenue: $63.0B$63.5B (Est. $61.63B) ๐ข - EPS (Non-GAAP): $23.00$23.70 (Est. $22.50) ๐ข $LLY CEO David Ricks: Lilly delivered another strong quarter with XX% revenue growth year-over-year driven by continued demand for our incretin portfolio". " We advanced Orforglipron through four"
X Link @TacticzH 2025-10-30T11:11Z 29.5K followers, 28.8K engagements
/topic/$6163b